Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.35 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30547579 | 1.00 | PDK1 (0.36) | PDK1PDK2PDK3PDK4DDR1 | |
| SCHEMBL23877457 | 0.93 | DDR1 (0.38) | PDK1PDK2PDK3PDK4DDR1 | |
| SCHEMBL23877569 | 0.85 | CNR2 (0.39) | SLC22A12 | |
| SCHEMBL31046860 | 0.85 | CNR2 (0.39) | SLC22A12 | |
| SCHEMBL23877560 | 0.85 | MRGPRX1 (0.39) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL22820229 | 0.85 | KDM1A (0.40) | DDR1CXCR5 | |
| SCHEMBL23877476 | 0.84 | TBXA2R (0.35) | SLC22A12TBXA2RALBCXCR5 | |
| SCHEMBL26188695 | 0.83 | PDK1 (0.36) | PDK1PDK2PDK3PDK4DDR1 | |
| SCHEMBL23877625 | 0.83 | PARP14 (0.38) | PDK1PDK2PDK3PDK4DDR1 | |
| SCHEMBL23877495 | 0.82 | TNF (0.35) | PDK1PDK2PDK3PDK4DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | PDK1 2441/4885PDK2 1094/4885PDK3 1799/4885 |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | PDK1 2441/4885PDK2 1094/4885PDK3 1799/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | PDK1 1922/4885PDK2 1680/4885PDK3 1869/4885 |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | PDK1 2441/4885PDK2 1094/4885PDK3 1799/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | PDK1 2441/4885PDK2 1094/4885PDK3 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.